Trial Profile

Pregnancy and Infant Outcomes in Anifrolumab Exposed Pregnancies Using PRegnancy Outcomes Intensive Monitoring (PRIM) Data: The Anifrolumab PRIM Program

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anifrolumab (Primary)
Indications Cutaneous lupus erythematosus; Lupus nephritis; Myositis; Scleroderma; Sjogren's syndrome; Systemic lupus erythematosus
Focus Adverse reactions
Sponsors AstraZeneca

Most Recent Events

25 Jun 2025 Planned End Date changed from 15 Apr 2031 to 30 Sep 2031.
25 Feb 2025 Planned initiation date changed from 28 Feb 2025 to 30 May 2025.
04 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com